Ascendis Pharma A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASND research report →
About the company
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
- CEO
- Jan Moller Mikkelsen
- IPO
- 2015
- Employees
- 1,017
- HQ
- Hellerup, DK
Price Chart
- Market Cap
- $17.05B
- P/E
- 29.22
- P/S
- 17.18
- P/B
- 30.30
- EV/EBITDA
- 1231.11
- Div Yield
- 0.00%
- Gross Margin
- 88.17%
- Op Margin
- -0.80%
- Net Margin
- 58.40%
- ROE
- -5641.90%
- ROIC
- 1.51%
- Revenue
- $691.71M · 90.22%
- Net Income
- $-219,034,140 · 42.07%
- EPS
- $-3.62 · 44.56%
- Op Income
- $-130,892,766
- FCF YoY
- 114.18%
- 52W High
- $274.89
- 52W Low
- $160.86
- 50D MA
- $233.87
- 200D MA
- $220.34
- Beta
- 0.36
- Avg Volume
- 782.48K
Get TickerSpark's AI analysis on ASND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 2, 26 | SMITH SCOTT THOMAS | buy | 100 |
| May 29, 26 | BIENAIME JEAN JACQUES | buy | 100 |
| May 29, 26 | BIENAIME JEAN JACQUES | buy | 200 |
| May 29, 26 | BIENAIME JEAN JACQUES | buy | 200 |
| May 29, 26 | SMITH SCOTT THOMAS | buy | 250 |
| Mar 18, 26 | SMITH SCOTT THOMAS | other | 0 |
| May 26, 26 | BIENAIME JEAN JACQUES | buy | 200 |
| May 26, 26 | BIENAIME JEAN JACQUES | buy | 200 |
| May 11, 26 | JENSEN FLEMMING STEEN | sell | 19,460 |
| Mar 23, 26 | BIENAIME JEAN JACQUES | other | 0 |
Our ASND coverage
Recent articles, reports, and earnings notes.
No research on ASND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASND report →Similar companies
Peers in the same neighborhood.